TCM
SLNO

TCG Crossover Management’s Soleno Therapeutics SLNO Stock Holding History

TCG Crossover Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-186,250
Closed -$15.6M – 47
2025
Q2 		$15.6M Sell
186,250
-88,750
-32% -$6.64M 1.78% 22
2025
Q1 		$19.6M Sell
275,000
-275,000
-50% -$13.4M 2.68% 16
2024
Q4 		$24.7M Hold
550,000
– – 2.42% 20
2024
Q3 		$27.8M Hold
550,000
– – 2.35% 19
2024
Q2 		$22.4M Hold
550,000
– – 2.34% 18
2024
Q1 		$23.5M Buy
+550,000
New +$24.9M 1.86% 22

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

TCG Crossover Management's SLNO Position: Q3 2025 in Review

TCG Crossover Management sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 186,250 shares — an estimated $15.6M sold.

TCG Crossover Management first reported a position in SLNO in Q1 2024 and held it in 6 quarters. The position peaked at $27.8M in Q3 2024. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • TCG Crossover Management reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • TCG Crossover Management sold 186,250 Soleno Therapeutics shares in Q3 2025, an estimated $15.6M.
  • TCG Crossover Management first reported a position in Soleno Therapeutics in Q1 2024 and held it in 6 quarters.
  • TCG Crossover Management's Soleno Therapeutics position peaked at $27.8M in Q3 2024.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on TCG Crossover Management's 13F filing for Q3 2025, filed 17 Nov 2025.